Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04397003 · ClinicalTrials.gov registry record · Phase 2

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

A Phase 2 study of Extensive-stage Small-cell Lung Cancer, sponsored by Washington University School of Medicine.

Active
Registry status
Phase 2
Development phase
6
Enrollment target
1
Study location

NCT04397003: Active Phase 2 study of Extensive-stage Small-cell Lung Cancer, sponsored by Washington University School of Medicine.

NCT04397003 is a Phase 2 study of Extensive-stage Small-cell Lung Cancer that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 6 participants, below the 175-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04397003, a Phase 2 study of Extensive-stage Small-cell Lung Cancer, is active but no longer recruiting, sponsored by Washington University School of Medicine.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

The investigators hypothesize that a personalized neoantigen vaccine combined with durvalumab will improve the progression free survival of patients with extensive state small cell lung cancer (ES-SCLC).

Primary Outcome

-Safety and tolerability will be measured by National Cancer Institute Common Terminology Criteria (NCI CTCAE) v 5.0

Conditions Studied

Extensive-stage Small-cell Lung Cancer

Interventions

  • DRUG Durvalumab
  • BIOLOGICAL Neoantigen DNA vaccine
  • DEVICE TDS-IM v2.0 Device
  • PROCEDURE Peripheral blood draws

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2022-03-30
Est. Completion 2029-09-30
Phase Phase 2
Washington University School of Medicine

1,502 total trials

What the registry record for NCT04397003 still lists

NCT04397003 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 175-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Durvalumab is the first listed.

NCT04397003 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT04397003 about?

NCT04397003 is a clinical study titled "Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer". The investigators hypothesize that a personalized neoantigen vaccine combined with durvalumab will improve the progression free survival of patients with extensive state small cell lung cancer (ES-SCLC).

What is the current status of trial NCT04397003?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2022-03-30. Estimated completion is 2029-09-30.

What conditions does trial NCT04397003 study?

This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.

What interventions are being tested in trial NCT04397003?

The interventions under investigation include: Durvalumab (DRUG), Neoantigen DNA vaccine (BIOLOGICAL), TDS-IM v2.0 Device (DEVICE), Peripheral blood draws (PROCEDURE).

Who is sponsoring clinical trial NCT04397003?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04397003 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Extensive-stage Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04397003's enrollment target sits among peer trials

6 26th of 25 the lowest of 25 other Extensive-stage Small-cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Extensive-stage Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04397003, the US trial registry maintained by the National Library of Medicine. NCT04397003 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.